Case Study: MEI Pharma accelerates cancer therapy development with Quotient Sciences Translational Pharmaceutics

MEI Pharma accelerates oncology development with Quotient Sciences' 400+ project expertise

MEI Pharma, a clinical-stage pharmaceutical company, sought to expedite the development of its novel cancer therapy ME-401. They leveraged Quotient Sciences' Translational Pharmaceutics® platform to accelerate the drug development process for this oral PI3K delta inhibitor.

Quotient Sciences applied its integrated Translational Pharmaceutics® platform, which combines real-time drug product manufacturing with clinical testing. This solution allowed for rapid drug product optimization and accelerated MEI Pharma's oncology program, successfully advancing ME-401 into clinical trials for chronic lymphocytic leukemia and follicular non-Hodgkin’s lymphoma.

MEI Pharma